The need for wider and appropriate utilization of aspirin and statins in the treatment and prevention of cardiovascular disease

References

• Hennekens CH. Increasing burden of cardiovascular disease: current knowledge and future directions for research on risk factors. Circulation97, 1095–1102 (1998).
   PubMed Web of Science ®Google Scholar
• Rosamond W, Flegal K, Friday G et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation115(5), e69–e171 (2007).
   PubMed Web of Science ®Google Scholar
• Murray CJL, Lopez AD. The Global Burden Of Disease: A Comprehensive Assessment Of Mortality And Disability From Diseases, Injuries, And Risk Factors In 1990 And Projected To 2020. Harvard University Press, MA, USA (1996).
   Google Scholar
• Mackay J, Mensah G (Eds). The Atlas of Heart Disease and Stroke. World Health Organization, (2004).
   Google Scholar
• Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years’ observations on male British doctors. BMJ328, 1519–1528 (2004).
   PubMed Web of Science ®Google Scholar
• Peto R, Chen ZM, Boreham J. Tobacco – the growing epidemic. Nat. Med.5, 15–17 (1999).
   PubMed Web of Science ®Google Scholar
• Liu BQ, Peto R, Chen ZM et al. Emerging tobacco hazards in China: 1. Retrospective proportional mortality study of one million deaths. BMJ317(7170), 1411–1422 (1998).
   PubMed Web of Science ®Google Scholar
• Niu SR, Yang GH, Chen ZM et al. Emerging tobacco hazards in China: 2. Early mortality results from a prospective study. BMJ317(7170), 1423–1424 (1998).
   PubMed Web of Science ®Google Scholar
• Haffner S on behalf of the IDEA Executive Committee. Waist circumference and Body Mass Index are both independently associated with cardiovascular disease. The International Day for the Evaluation of Abdominal Obesity (IDEA) survey. Circulation116, 1942–1951 (2007).
   Google Scholar
• Willett WC, Manson JE, Stampfer MJ et al. Weight and weight change in relation to risk of coronary heart disease in women: a 14-year follow-up. JAMA273, 461–465 (1995).
   PubMed Web of Science ®Google Scholar
• Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999–2000. JAMA288, 1723–1727 (2002).
   PubMed Web of Science ®Google Scholar
• Hennekens CH, Buring JE. Epidemiology in Medicine. Little, Brown, & Co., MA, USA (1987).
   Google Scholar
• Williams A, Hennekens CH. The role of aspirin in cardiovascular diseases: forgotten benefits. Expert Opin. Pharmacother.5, 109–115 (2004).
   PubMed Web of Science ®Google Scholar
• Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol.231, 232–235 (1971).
   PubMedGoogle Scholar
• Anti-Platelet Trialists Collaboration. Secondary prevention of vascular disease by prolonged anti-platelet therapy. BMJ296, 320–331 (1988).
   PubMed Web of Science ®Google Scholar
• Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high-risk patients. BMJ324, 71–86 (2002).
   PubMed Web of Science ®Google Scholar
• Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA285(19), 2486–2497 (2001).
   PubMed Web of Science ®Google Scholar
• ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction. Lancet2(8607), 349–360 (1988).
   PubMed Web of Science ®Google Scholar
• Hennekens CH, Jonas MA, Buring JE. The benefits of aspirin in acute myocardial infarction: still a well-kept secret in the U.S. Arch. Intern. Med.154, 37–39 (1994).
   PubMedGoogle Scholar
• The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med.345, 494–502 (2001).
   PubMed Web of Science ®Google Scholar
• Chen Z, Jiang L, Chen Y et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet366, 1607–1621 (2005).
   PubMed Web of Science ®Google Scholar
• International Stroke Trial Collaborative Group. The International Stroke Trial (IST): a randomized trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet349, 1569–1581 (1997).
   PubMed Web of Science ®Google Scholar
• Chinese Acute Stroke Trial (CAST) Collaborative Group. CAST: randomized placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet349, 1641–1649 (1997).
   PubMed Web of Science ®Google Scholar
• Steering Committee of the Physicians’ Health Study Research Group. Preliminary report on the aspirin component of the ongoing Physicians’ Health Study. N. Engl. J. Med.318, 262–264 (1988).
   PubMed Web of Science ®Google Scholar
• Steering Committee of the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health Study. N. Engl. J. Med.321, 129–135 (1989).
   PubMed Web of Science ®Google Scholar
• Peto R, Gray R, Collins R, Hernnekens CH et al. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ296, 313–316 (1988).
   PubMed Web of Science ®Google Scholar
• The Medical Research Council’s General Practice Research Framework. Thrombosis Prevention Trial: Randomised trial of low intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet351, 233–240 (1998).
   PubMed Web of Science ®Google Scholar
• Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet351, 1755–1762 (1998).
   PubMed Web of Science ®Google Scholar
• Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. Lancet357, 879–895 (2001).
   Google Scholar
• Eidelman RS, Hebert PR, Weisman S, Hennekens CH: An update on aspirin in the primary prevention of cardiovascular disease. Arch. Intern. Med.163, 2006–2010 (2003).
   Google Scholar
• Ridker PM, Cook NR, Lee IM et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N. Engl. J. Med.352, 1293–1304 (2005).
   PubMed Web of Science ®Google Scholar
• Levin RI. The puzzle of aspirin and sex. N. Engl. J. Med.352, 1366–68 (2005).
   PubMed Web of Science ®Google Scholar
• Becker DM, Segal J, Vaidya D et al. Sex differences in platelet reactivity and response to low-dose aspirin therapy. JAMA295, 1420–1427 (2006).
   PubMed Web of Science ®Google Scholar
• Levin RI, Harpel PC, Weil D, Chang TS, Rifkin DB. Aspirin inhibits vascular plasminogen activator activity. J. Clin. Invest.74, 571–580 (1984).
   PubMed Web of Science ®Google Scholar
• Bartolucci AA, Howard G. Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin. Am. J. Cardiol.98, 746–750 (2006).
   PubMed Web of Science ®Google Scholar
• Wilson PWF, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation97, 1837–1847 (1998).
   PubMed Web of Science ®Google Scholar
• United States Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events-recommendations and rationale. Ann. Intern. Med.136, 157–160 (2002).
   PubMed Web of Science ®Google Scholar
• Pearson TA, Blair SN Daniels SR et al. American Heart Association Science Advisory and Coordinating Committee. American Heart Association guidelines for primary prevention of cardiovascular disease and stroke: 2002 Update: Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation106(3), 388–391 (2002).
   PubMed Web of Science ®Google Scholar
• Garcia Rodriguez LA, Hernandez-Diaz S, de Abajo FJ. Association between aspirin and upper gastrointesitinal complications: systematic review of epidemiologic studies. Br. J. Clin. Pharmacol.52, 563–571 (2001).
   PubMed Web of Science ®Google Scholar
• Nelson M, Rerid C, Beilin L et al. Aspirin in Reducing Events in the Elderly (ASPREE) Study Group. Rationale for a trial of low-dose aspirin for the primary prevention of major adverse cardiovascular events and vascular dementia in the elderly. Drugs Aging20(12), 897–903 (2003).
   Google Scholar
• Hennekens CH, Hollar D, Baigent C. Sex related differences in response to aspirin: an untested hypothesis. Nat. Clin. Pract. Cardiovasc. Med.3, 2–5 (2006).
   Google Scholar
• The Task Force on the Use of Antiplatelet Agents in Patients with Atherosclerotic Cardiovascular Diseases of the European Society of Cardiology. Expert consensus document on the use of antiplatelet agents. Eur. Heart. J.25, 166–181 (2004).
   PubMed Web of Science ®Google Scholar
• UK-TIA Study Group. United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: interim results. Br. Med. J. (Clin. Res. Ed.)296(6618), 316–320 (1988).
   PubMed Web of Science ®Google Scholar
• Reilly IA, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood69, 180–186 (1987).
   PubMed Web of Science ®Google Scholar
• Hennekens, CH, Sechenova O, Hollar D, Serebruany V. Dose of aspirin in the treatment and prevention of cardiovascular disease; current and future directions. J. Cardiovasc. Pharm. & Ther.11(3), 1–7 (2006).
   Google Scholar
• Baigent C, Keech A, Kearney PM et al. Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet366, 1267–1278 (2005).
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tuzcu EM, Schoenhagen P et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA291, 1071–1080 (2004).
   PubMed Web of Science ®Google Scholar
• Cannon CP, Braunwald E, McCabe CH et al. for the Pravastatin or Atorvastatin Evaluation and Infection Therapy Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med.350(15), 1495–1504 (2004).
   PubMed Web of Science ®Google Scholar
• LaRosa JC, Grundy SM, Waters DD et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med.352(14), 1425–1435 (2005).
   PubMed Web of Science ®Google Scholar
• Nissen SE, Nicholls SJ, Sipahi I et al.; for the ASTEROID Investigators. Effect of Very High-Intensity Statin Therapy on Regression of Coronary Atherosclerosis: The ASTEROID Trial. JAMA295, 1556–1565 (2006).
   PubMed Web of Science ®Google Scholar
• Crouse JR III, Raichlen JS, Riley WA et al., for the METEOR Study Group. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: The METEOR Trial. JAMA297, 1344–1353 (2007).
   PubMed Web of Science ®Google Scholar
• Novela C, Hennekens CH. Hypothesis: Atorvastatin has unique pleiotropic effects leading to early clinical benefits. J. Cardiovasc. Pharm. Ther.9(1), 61–63 (2004).
   PubMed Web of Science ®Google Scholar
• Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and deaths with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl J. Med.339(19), 1349–1357 (1998).
   PubMed Web of Science ®Google Scholar
• Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N.Engl. J. Med.335, 1001–1019 (1996).
   PubMed Web of Science ®Google Scholar
• Jukema JW, Bruschke AVG, van Boven AJ et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: the Regression Growth Evaluation Study (REGRESS) Circulation91, 2528–2540 (1995).
   PubMed Web of Science ®Google Scholar
• Pitt B, Mancini GB, Ellis SG et al. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC I): reduction in atherosclerosis progression and clinical events. J. Am. Col. Cardiol.26, 1133–1139 (1995).
   PubMed Web of Science ®Google Scholar
• Crouse JR, Bylington RP, Bond MG et al. Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC II). Am. J. Cardiol.75, 455–459 (1995).
   PubMed Web of Science ®Google Scholar
• Hennekens CH, Sacks F, Tonkin A et al. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analysis. Arch. Int. Med.164(1), 40–44 (2004).
   PubMed Web of Science ®Google Scholar
• Hennekens CH, Hollar D, Eidelman RS, Agatston AS. Update for primary healthcare providers: recent statin trials and revised National Cholesterol Education Program III guidelines. Medscape General Medicine.8(1), 54 (2006).
   Google Scholar